Ace Infectious Announces Antimicrobial Peptide Development Services to Drive Forward Drug Development Against Superbugs
Ace Infectious, a one-stop shop for researchers devoted to making advancements in infectious diseases including superbugs and H. pylori, is thrilled to announce the launch of its antimicrobial peptide development services. This ground-breaking service will revolutionize drug development efforts against the growing threat of superbugs, providing innovative solutions to combat infectious diseases.
To Fight Superbugs, Ace Infectious Unveils Phage Therapy Development Services
Ace Infectious announced today the launch of its phage therapy development services initiated with the aim of combating the global threat of superbugs. As a biotechnology company specializing in anti-superbug drug and therapy development, Ace Infectious is dedicated to providing innovative, effective, and safe development services to support scientific communities addressing the urgent need for alternative therapies to fight drug-resistant bacterial infections.